Discover why Blue Owl Capital’s asset-light model, stable revenue streams, and growth prospects make it a long-term buy for ...
TFS Financial (TFSL) is deeply undervalued, trading at 7x earnings and 39% of book value, with a robust 8.3% dividend yield.
As the Jefferies Healthcare conference gets underway this week in London, pharmaphorum had the chance to connect with the CEO ...
During the upcoming Venice Biennale, Crystal Bridges Museum will stage an exhibition dedicated to the art singer-songwriter ...
The autoimmune disorder destroys the body's ability to produce insulin. Some patients in experimental trials have gotten it back.
Latest research indicates that India is vaulting past the experimentation stage and into full-scale AI deployment, with ...
Alembic Technologies, a pioneer in Causal AI for the enterprise, today announced it has secured $145 million in Series B and growth funding - a 15.7x increase in valuation over their Series A round.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback